***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: The objective of our study was to compare prospect ively the QoL in long‐term ovarian cancer survivors with short‐term survivors and to explore discriminating variables between short‐term and long‐term survival . Thirty‐three patients were included , 22 died within 5 years post diagnosis and 11 survived beyond 10 years .  QoL data were collected pre‐treatment ( baseline ) , 1‐year post diagnoses and for long‐term survivors 10 years post‐treatment using the EORTC QLQ‐C30 . At baseline , there was no difference in terms of FIGO stage , residual tumor and adjuvant chemotherapy . Significantly , more short‐term survivors ( 96 % ) had intra operative ascites as compared to long‐term survivors ( 55 % ) ( p=0.01 ) . Before treatment , short‐term survivors had clinical ly significantly lower QoL scores on the physical functioning ( mean 75.45 ) and role functioning scale ( mean 68.94 ) compared to long‐term survivors ( mean 68.94 and 84.85 , respectively ) . They also reported higher levels of symptoms . One year post‐diagnosis , QoL scores were comparable in most domains . Long‐term survivors had a significantly better global QoL but more insomnia . Emotional functioning and global QoL/health status improved significantly from baseline to 1‐year post‐diagnosis and remained relatively stable at the 10‐year follow‐up . The presence of intra operative ascites and a supporting social network were identified as significant variables that discriminated between short‐term and long‐term survival . Compared to a reference sample , long‐term survivors showed similar QoL scores but more dyspnoea . Although ovarian cancer patients do not belong to the most prevalent survivor population s , we found that long‐term survivors have QoL scores similar to females without a history of cancer Background Surgeons , along with the Centers for Disease Control and Prevention , emphasize the importance of managing symptoms and improving the quality of life of cancer survivors . A 2008 meta- analysis of mindfulness-based stress reduction ( MBSR ) concluded that this technique might improve patients ’ adjustment to their disease . However , r and omized controlled trials using st and ardized measures for evaluating MBSR are limited . The primary objective of this study was to evaluate , using valid and reliable measures , the effects of a unique , interactive , 8-week cancer recovery and wellness program on symptoms and quality of life of female cancer survivors . Methods Sixty-eight female cancer patients were r and omized into either an intervention or waitlisted control group . Patients were evaluated using the  Symptoms Checklist ( SCL-90-R ) , the European Organization for Research and Treatment of Cancer Quality of Life Question naire ( EORTC QLQ-30 ) , and the Symptoms of Stress Inventory ( SOSI ) . Results Of the participants , 70.6 % were breast cancer survivors . Mean age was 57.5 years ( treatment group ) and 56.4 years ( control group ) . Between-group demographic differences were not significant ( P > 0.6 ) . The treatment group improved significantly on the EORTC QLQ-30 ( P = 0.005 ) , on six of the eight SOSI subscales ( P ≤ 0.049 ) , and on both SCL-90-R subscales ( P ≤ 0.023 ) , while the control group did not improve on any of these measures ( P > 0.2 ) . Conclusion The MBSR-based cancer recovery and wellness intervention improved the symptoms and quality of life of this largely breast cancer survivor population across a variety of cancer symptoms and quality -of-life measures OBJECTIVE The aims of this study were to compare the quality of life ( QOL ) of women with different cancer sites ; to identify predictors of QOL ; and to examine the agreement between patient self-reported QOL and QOL ratings provided by clinicians and significant others . METHODS A prospect i ve study was conducted including 248 patients with gynecologic and breast cancer .  QOL data  were collected at six time points before , during , and after treatment , using the EORTC QLQ-C30 and the Spitzer QL index ( QL-I ) .  RESULTS Baseline assessment s showed comparable QOL scores among patients with different gynecologic malignancies and breast cancer . During active treatment breast cancer patients had significantly higher mean scores in physical functioning compared to women with gynecologic cancers and higher scores in role functioning compared to patients with cervical cancer . After completion of treatment there were no statistically significant differences in QOL among the groups . For all women , global QOL and emotional functioning were mostly affected during and after treatment . Regression analysis showed that patients ' global QOL was significantly predicted by severity of surgery ( t = 3.903 , P < 0.01 ) and pretreatment performance status ( t = 3.116 , P = < 0.01 ) . Comorbidity , family support , number of treatments , age , and stage of disease were not predictive . The comparison of patient self-rated QOL and observer-rated QOL showed that the QL-I mean scores of health providers and relatives were generally in close agreement with those of patients . Intraclass correlations were moderate to high during active treatment and excellent after completion of treatment . CONCLUSION In female cancer patients , global QOL and emotional functioning are mostly affected during the course of disease , independent of their diagnosis . Significant others and health professionals are able to provide useful information on QOL of patients recovering from cancer The objective of this study was to determine current practice with regards to follow-up after gynecological malignancy . A question naire survey of all lead clinicians in gynecological cancer centers in Engl and was done . The most common duration of routine follow-up was 5 years for all of the main gynecological cancers ( ovarian , endometrial , vulval , and cervical ) . The most common follow-up patterns were three monthly for 2 years then six monthly for 3 years after ovarian cancer ; three monthly for the first year , four monthly for the second year , six monthly for the third year then annually for 1 year after endometrial cancer ; three monthly for the first year , four monthly for the second year , six monthly for the third and fourth years , then annually for 1 year after vulval cancer ; three monthly for the first year , four monthly for the second year , six monthly for the third and fourth years , then annually for 1 year after cervical cancer . The test for CA125  was routinely performed by 67 % of cancer networks to detect recurrence after ovarian cancer . Routine follow-up after gynecological cancer continues to be st and ard practice , despite limited evidence to support its use . Prospect i ve research is needed to determine best practice The aim of this study was to derive population -based norms for women completing the EORTC QLQ-C30 version 1  which is design ed for use with patients who have cancer . The study was conducted using two different question naires : one design ed for use in female patients with breast cancer , the other for those with gynaecological cancers , but both including the EORTC QLQ-C30 . The women were drawn from the Danish Central Population Register without knowledge of their health status and divided at r and om between the two question naires . All procedures for collecting data were identical . The response rate for those receiving the gynaecological cancer ( GS ) question naire was 49 % and it was 71 % for the breast cancer ( BS ) question naire . Detailed comparison between the two sample s revealed several EORTC QLQ-C30 items showing a clear difference in distribution of scores between them . Because of this and the possible bias due to the relative low age-related response rate in GS , only the results from the BS are used for constructing norms . The norms cover all 30 single items on the EORTC QLQ-C30 and the nine derived scales , for women in four 10-year age groups commencing at 30 years and for those aged 70 - 75 . Clear trends in , for example , declining ability to undertake strenuous activity are illustrated and quantified . Levels of certain symptoms , such as pain , are surprisingly high although it is recognized that the population sample d will contain a proportion of women with active disease including cancer . We recommend the use of these norms both as an aid to the clinical assessment of an individual patient , and to assist in the interpretation of clinical trial and longitudinal quality of life data . As a secondary result , we note that a population -based sample will have a lower response rate to a question naire with more questions , especially if many of these extra questions are on sexual issues This study defines the psychometric properties of the European Organisation for Research and Treatment of Cancer ( EORTC ) quality of life ( QOL ) question naire design ed to measure the QOL of patients with ovarian cancer . The ovarian cancer module ( EORTC QLQ-OV28 ) was developed to supplement the EORTC QLQ-C30 . The core question naire and the QLQ-OV28 were prospect ively administered to 368 ovarian cancer patients after they had been treated with radical or debulking surgery followed by chemotherapy .  The QLQ-OV28 module assesses abdominal/gastrointestinal symptoms , peripheral neuropathy , other chemotherapy side-effects , hormonal/menopausal symptoms , body image , attitude to disease/treatment and sexual functioning . Question naires were well accepted by patients , baseline compliance rates were 86 % , 72 % provided a second assessment , less than 3 % of the items had missing data . Multi-trait scaling analyses confirmed the hypothesised scales . All hypothesised scales exhibited good psychometric properties . These results support the clinical and psychometric validity of the EORTC QLQ-OV28 module as a supplement to the EORTC QLQ-C30 
    Output:
    
AUTHORS ' CONCLUSIONS We found no evidence to make an informed decision about PROMs for follow-up after gynaecological cancer .